BACKGROUND: Nephrotoxicity of cancer therapy using radiolabeled somatostatin analogues such as octreotide is due to ultrafiltration and reuptake by proximal tubular cells (PTCs). The mechanism of uptake is unknown. It could occur either by receptor-mediated endocytosis via a somatostatin receptor or, alternatively, the multiligand megalin/cubilin tandem receptor, or by fluid-phase endocytosis. To define the mechanisms of internalization and to identify potential receptors, we have studied the uptake and processing of octreotide by the PTC-derived opossum kidney (OK) cell line. METHODS: We compared the kinetics of uptake and fate of (111)In-diethylenetriamine pentaacetic acid (DTPA)-D-Phe(1)-octreotide and (125)I-human serum albumin ((125)I-HSA). To determine the contribution of receptor-mediated endocytosis, we tested competition for uptake by octreotide and somatostatin and by various megalin/cubilin ligands [receptor-associated protein (RAP), albumin, transferrin, insulin, polymixin B] or basic amino acids. The subcellular localization of fluorescein isothiocyanate (FITC)-D-Phe(1)-octreotide was studied by confocal microscopy. RESULTS: Kinetics of uptake of (111)In-DTPA-D-Phe(1)-octreotide and (125)I-HSA by OK cells were comparable, but only the somatostatin analogue was significantly retained intact. All megalin/cubilin ligands and basic amino acids strongly inhibited (125)I-HSA uptake, but these could not compete for >50% of (111)In-DTPA-D-Phe(1)-octreotide uptake. The same was found for somatostatin and octreotide. The noncompetable uptake of (111)In-DTPA-D-Phe(1)-octreotide was comparable to the clearance of Lucifer Yellow, a marker of fluid-phase endocytosis. By confocal microscopy, FITC-D-Phe(1)-octreotide colocalized with transferrin in endosomes, then accumulated in lysosomes. CONCLUSION: Receptor-mediated endocytosis via megalin/cubilin and fluid-phase endocytosis contribute about equally to the uptake of radiolabeled somatostatin analogues by OK cells.
BACKGROUND:Nephrotoxicity of cancer therapy using radiolabeled somatostatin analogues such as octreotide is due to ultrafiltration and reuptake by proximal tubular cells (PTCs). The mechanism of uptake is unknown. It could occur either by receptor-mediated endocytosis via a somatostatin receptor or, alternatively, the multiligand megalin/cubilin tandem receptor, or by fluid-phase endocytosis. To define the mechanisms of internalization and to identify potential receptors, we have studied the uptake and processing of octreotide by the PTC-derived opossum kidney (OK) cell line. METHODS: We compared the kinetics of uptake and fate of (111)In-diethylenetriamine pentaacetic acid (DTPA)-D-Phe(1)-octreotide and (125)I-human serum albumin ((125)I-HSA). To determine the contribution of receptor-mediated endocytosis, we tested competition for uptake by octreotide and somatostatin and by various megalin/cubilin ligands [receptor-associated protein (RAP), albumin, transferrin, insulin, polymixin B] or basic amino acids. The subcellular localization of fluorescein isothiocyanate (FITC)-D-Phe(1)-octreotide was studied by confocal microscopy. RESULTS: Kinetics of uptake of (111)In-DTPA-D-Phe(1)-octreotide and (125)I-HSA by OK cells were comparable, but only the somatostatin analogue was significantly retained intact. All megalin/cubilin ligands and basic amino acids strongly inhibited (125)I-HSA uptake, but these could not compete for >50% of (111)In-DTPA-D-Phe(1)-octreotide uptake. The same was found for somatostatin and octreotide. The noncompetable uptake of (111)In-DTPA-D-Phe(1)-octreotide was comparable to the clearance of Lucifer Yellow, a marker of fluid-phase endocytosis. By confocal microscopy, FITC-D-Phe(1)-octreotide colocalized with transferrin in endosomes, then accumulated in lysosomes. CONCLUSION: Receptor-mediated endocytosis via megalin/cubilin and fluid-phase endocytosis contribute about equally to the uptake of radiolabeled somatostatin analogues by OK cells.
Authors: Edgar J Rolleman; Roelf Valkema; Marleen Melis; Marion de Jong; Eric P Krenning; Theo J Visser; Edgar J Rolleman Journal: Eur J Nucl Med Mol Imaging Date: 2006-06 Impact factor: 9.236
Authors: Mark A Bryniarski; Bei Zhao; Lee D Chaves; Jakob Hauge Mikkelsen; Benjamin M Yee; Rabi Yacoub; Shichen Shen; Mette Madsen; Marilyn E Morris Journal: AAPS J Date: 2021-03-07 Impact factor: 4.009
Authors: Wânia R Lima; Kleber S Parreira; Olivier Devuyst; Adrian Caplanusi; Francisca N'kuli; Benoit Marien; Patrick Van Der Smissen; Pedro M S Alves; Pierre Verroust; Erik I Christensen; Fabiola Terzi; Karl Matter; Maria S Balda; Christophe E Pierreux; Pierre J Courtoy Journal: J Am Soc Nephrol Date: 2010-02-04 Impact factor: 10.121
Authors: Virginie Janssens; Héloïse P Gaide Chevronnay; Sandrine Marie; Marie-Françoise Vincent; Patrick Van Der Smissen; Nathalie Nevo; Seppo Vainio; Rikke Nielsen; Erik I Christensen; François Jouret; Corinne Antignac; Christophe E Pierreux; Pierre J Courtoy Journal: J Am Soc Nephrol Date: 2019-09-23 Impact factor: 10.121
Authors: Edgar J Rolleman; Marleen Melis; Roelf Valkema; Otto C Boerman; Eric P Krenning; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2009-11-14 Impact factor: 9.236
Authors: Edgar J Rolleman; Peter P M Kooij; Wouter W de Herder; Roelf Valkema; Eric P Krenning; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2007-06-02 Impact factor: 9.236
Authors: Erik Vegt; Marleen Melis; Annemarie Eek; Monique de Visser; Maarten Brom; Wim J G Oyen; Martin Gotthardt; Marion de Jong; Otto C Boerman Journal: Eur J Nucl Med Mol Imaging Date: 2010-12-18 Impact factor: 9.236
Authors: Erik Vegt; Annemarie Eek; Wim J G Oyen; Marion de Jong; Martin Gotthardt; Otto C Boerman Journal: Eur J Nucl Med Mol Imaging Date: 2009-09-01 Impact factor: 9.236